-+ 0.00%
-+ 0.00%
-+ 0.00%

Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M

Benzinga·06/25/2026 05:41:04
Listen to the news

Basic and diluted loss per share remained stable at CHF 0.01 per share for the three-month periods ended March 31, 2026 and 2025.